HK1251553A1 - 苯並異惡唑衍生物鹽 - Google Patents

苯並異惡唑衍生物鹽

Info

Publication number
HK1251553A1
HK1251553A1 HK18110880.2A HK18110880A HK1251553A1 HK 1251553 A1 HK1251553 A1 HK 1251553A1 HK 18110880 A HK18110880 A HK 18110880A HK 1251553 A1 HK1251553 A1 HK 1251553A1
Authority
HK
Hong Kong
Prior art keywords
derivative salt
benzisoxazole derivative
benzisoxazole
salt
derivative
Prior art date
Application number
HK18110880.2A
Other languages
English (en)
Inventor
Numata Toyoharu
Sudo Masaki
Sun Xufeng
Original Assignee
拉夸里亞創藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拉夸里亞創藥株式會社 filed Critical 拉夸里亞創藥株式會社
Publication of HK1251553A1 publication Critical patent/HK1251553A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18110880.2A 2014-05-20 2018-08-23 苯並異惡唑衍生物鹽 HK1251553A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462000687P 2014-05-20 2014-05-20

Publications (1)

Publication Number Publication Date
HK1251553A1 true HK1251553A1 (zh) 2019-02-01

Family

ID=54553701

Family Applications (2)

Application Number Title Priority Date Filing Date
HK17105284.5A HK1231483A1 (zh) 2014-05-20 2017-05-24 苯並異噁唑衍生物的鹽
HK18110880.2A HK1251553A1 (zh) 2014-05-20 2018-08-23 苯並異惡唑衍生物鹽

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK17105284.5A HK1231483A1 (zh) 2014-05-20 2017-05-24 苯並異噁唑衍生物的鹽

Country Status (13)

Country Link
US (1) US9988370B2 (zh)
EP (1) EP3145926B1 (zh)
JP (1) JP6572414B2 (zh)
KR (1) KR102471082B1 (zh)
CN (2) CN107074837B (zh)
BR (1) BR112016024213A2 (zh)
CA (1) CA2944982C (zh)
ES (1) ES2747989T3 (zh)
HK (2) HK1231483A1 (zh)
MX (1) MX366985B (zh)
RU (1) RU2679619C2 (zh)
TW (1) TWI672300B (zh)
WO (1) WO2015178020A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015178020A1 (en) * 2014-05-20 2015-11-26 Raqualia Pharma Inc. Benzisoxazole derivative salt

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2003265681A1 (en) * 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
ES2523459T3 (es) * 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
SG183111A1 (en) * 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
BR112013021750A2 (pt) * 2011-03-23 2016-10-18 Raqualia Pharma Inc uso de ácido 4-{[4-({[4-(2,2,2-trifluoretoxi)-1,2-benzisoxazol-3-il]-oxi}metil)piperidina-1-il]metil}tetrahidro-2h-pirano-4-carboxílico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para o tratamento de doenças gastrointestinais, método para o tratamento de doenças gastrointestinais em um sujeito animal, incluindo um sujeito mamífero, método para o tratamento de doenças gastrointestinais e ácido 4-{[4-({[4-(2,2,2-trifluoretoxi)-1,2-benzisoxazol-3-il]-oxi}metil)piperidina-1-il]metil}tetrahidro-2h-pirano-4-carboxílico ou um sal farmaceuticamente aceitável do mesmo
JP5608873B2 (ja) 2011-05-18 2014-10-15 ラクオリア創薬株式会社 ４−｛［４−（｛［４−（２，２，２−トリフルオロエトキシ）−１，２−ベンズイソオキサゾール−３−イル］オキシ｝メチル）ピペリジン−１−イル］メチル｝−テトラヒドロ−２ｈ−ピラン−４−カルボン酸の多形形態
WO2015178020A1 (en) * 2014-05-20 2015-11-26 Raqualia Pharma Inc. Benzisoxazole derivative salt

Also Published As

Publication number Publication date
KR102471082B1 (ko) 2022-11-25
RU2016149650A3 (zh) 2018-11-30
RU2016149650A (ru) 2018-06-20
WO2015178020A1 (en) 2015-11-26
JP2017515868A (ja) 2017-06-15
EP3145926B1 (en) 2019-07-03
TWI672300B (zh) 2019-09-21
CN107074837A (zh) 2017-08-18
HK1231483A1 (zh) 2017-12-22
US20170081318A1 (en) 2017-03-23
US9988370B2 (en) 2018-06-05
EP3145926A4 (en) 2017-12-27
EP3145926A1 (en) 2017-03-29
CN108329305A (zh) 2018-07-27
CN107074837B (zh) 2020-07-28
BR112016024213A2 (pt) 2017-08-15
JP6572414B2 (ja) 2019-09-11
MX366985B (es) 2019-08-01
KR20170007737A (ko) 2017-01-20
TW201625602A (zh) 2016-07-16
RU2679619C2 (ru) 2019-02-12
CA2944982A1 (en) 2015-11-26
MX2016014948A (es) 2017-05-25
CA2944982C (en) 2022-06-07
ES2747989T3 (es) 2020-03-12

Similar Documents

Publication Publication Date Title
ZA201704602B (en) Dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
IL249356B (en) A derivative of 2-acylaminothiazole or its salt
PT3131898T (pt) Derivados de fluoroalquilfluoreno
IL248773A0 (en) History of naphthyridinedione
PL3418273T3 (pl) Pochodne flawaglin
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
IL248772A0 (en) A consequence of cyclohexyl pyridine
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
ZA201604927B (en) Aminopyrazolone derivative
HK1251553A1 (zh) 苯並異惡唑衍生物鹽
SG11201605072VA (en) Azaindole derivative
TWM489496U (en) Fishhook